Protein / target
RNA-directed RNA polymerase L
Protein at a glance
Biological role
MRNA 5'-cap (guanine-N7-)-methyltransferase
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
RNA-directed RNA polymerase that catalyzes the transcription of viral mRNAs, their capping and polyadenylation.
View complete UniProt function annotationHide complete annotation
RNA-directed RNA polymerase that catalyzes the transcription of viral mRNAs, their capping and polyadenylation. The template is composed of the viral RNA tightly encapsidated by the nucleoprotein (N). The viral polymerase binds to the genomic RNA at the 3' leader promoter, and transcribes subsequently all viral mRNAs with a decreasing efficiency. The first gene is the most transcribed, and the last the least transcribed. The viral phosphoprotein acts as a processivity factor. Capping is concomitant with initiation of mRNA transcription. Indeed, a GDP polyribonucleotidyl transferase (PRNTase) adds the cap structure when the nascent RNA chain length has reached few nucleotides. Ribose 2'-O methylation of viral mRNA cap precedes and facilitates subsequent guanine-N-7 methylation, both activities being carried by the viral polymerase. Polyadenylation of mRNAs occur by a stuttering mechanism at a slipery stop site present at the end viral genes. After finishing transcription of a mRNA, the polymerase can resume transcription of the downstream gene
Subcellular location
Domains and Gene Ontology detail (12)Hide
Domains & features
Gene Ontology
- Chost cell cytoplasm
- Cvirion component
- FATP binding
- FGTPase activity
- Fmetal ion binding
- FmRNA 5'-cap (guanine-N7-)-methyltransferase activity
- FRNA polymerase activity
- FRNA-directed RNA polymerase activity
- Pnegative stranded viral RNA replication
- Pnegative stranded viral RNA transcription
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Transcriptional regulation
- ·RNA-directed RNA polymerase that catalyzes the transcription of viral mRNAs, their cappi…
- ·negative stranded viral RNA transcription
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
RNA-directed RNA polymerase L inhibitor
Indicated for Coronavirus Infections, COVID-19, Severe Acute Respiratory Syndrome, Virus Diseases
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Indication expanded
Indication expansion: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Indication expanded
Indication expansion: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- New publicationEffect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.